[Correspondence] Post-trial responsibilities beyond post-trial access
What happens at the end of a trial when a patient responds to an investigational medication and benefits considerably? Many people believe that this patient should continue to receive the beneficial drug. This belief underlies the idea of post-trial access—providing investigational interventions post-trial to participants who benefited from them—and was formally introduced by the Declaration of Helsinki in 2000. But even if this patient did not benefit from the investigational medication, doing nothing for them at the end of the trial seems ethically problematic.